Avalyn Pharma Inc. Common Stock (AVLN) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-0.96x
Avalyn Pharma Inc. Common Stock (AVLN) has a Cash Flow-to-Debt Ratio of -0.96x as of June 2026, meaning its operating cash flow of $-26.08 Million could theoretically repay -1% of its total liabilities ($27.10 Million) in one year. See financial agility of Avalyn Pharma Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.96x
Operating CF / Total Liabilities
Operating Cash Flow
$-26.08 Million
USD
Total Liabilities
$27.10 Million
USD
Data as of
Jun 2026
Most recent filing
Avalyn Pharma Inc. Common Stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Avalyn Pharma Inc. Common Stock across 2 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Avalyn Pharma Inc. Common Stock.
Annual Cash Flow-to-Debt Ratio for Avalyn Pharma Inc. Common Stock (2024–2025)
Year-by-year debt coverage analysis for Avalyn Pharma Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.21x | $-81.48 Million | $387.54 Million | ▼ -30.0% |
| 2024 | -0.16x | $-48.37 Million | $299.04 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.